from concepts to biomarkers

& innovations in precision medicine

17 research teams,

9 platforms, 3 hosted biotechs

our state-of-the-art tools,

for cancer research

in the heart of a campus dedicated to applied cancer research...

...and Montpellier,

a city historically linked to medical research and teaching

the IRCM research teams
the IRCM research teams

L'Institut de Recherche en Cancérologie de Montpellier :
«Together, let's push the boundaries»


jeudi 27 mai 2021, 11h, Séminaire promotionnel

Chady JaberSyntego Inc“ How to Use the Power of CRISPR in Functional Genomics and Biomarkers Discovery”This seminar dedicated to researchers at the IRCM will cover the following topics:    • CRISPR Experimental Design and Optimization (Knock-outs and Knock-ins)     • Synthego robust loss of function screens for confident target discovery    • Using CRISPR to uncover protein functions and pathway analysis Join us for an interactive session about the latest CRISPR advances and applications. Discover the impact of CRISPR in cancer and genetic disease research. Inscription obligatoire :
En savoir plus

mercredi 5 mai à 11h00, séminaire MAbImprove

Sally Wardprofesseur d'immunologie moléculaire et directrice de l'immunologie translationnelle au Centre d'immunologie du cancer de la faculté de médecine de l'Université de Southampton"Targeting subcellular trafficking pathways to  design antibody-based therapeutics for cancer and autoimmunity"Professors Sally Ward and Raimund Ober have recently relocated their research group from the USA to Southampton. Their interdisciplinary research program is dedicated to the use of protein engineering to develop novel antibody-based therapeutics. The identification in the Ward/Ober laboratory of the Fc receptor, FcRn, as a regulator of IgG levels and transport has resulted in significant interest in targeting FcRn in biopharma. Extensive analyses of FcRn behaviour, including subcellular trafficking studies, have led to collaborations with biopharma to develop several therapeutics that are based on modulating the interactions of IgG with FcRn. For example, one such therapeutic (Efgartigimod) that inhibits FcRn activity has been developed in collaboration with Argenx, and has recently been successfully used in phase 3 trials to treat antibody-mediated autoimmune diseases. "The presentation will cover how a combination of antibody engineering, fluorescence microscopy and mouse disease models have been used to inform the design of therapeutics to modulate the dynamic behavior of antibodies for the treatment of autoimmunity. In particular, the targeting of the MHC Class I-related receptor, FcRn, that recycles and transports IgG to maintain IgG homeostasis will be discussed. The generation of engineered antibody-drug conjugates that are designed to deliver their cytotoxic payload more efficiently to tumor cells will also be presented"
En savoir plus

Mercredi 19 Mai à 11h, Séminaire MAbImprove

Julie BonnereauPhD student – INSERM U1160, Intestinal Immunity in Inflammation and Cancer - Hôpital Saint Louis, Paris « Targeting the CD39/CD73 adenosinergic pathway in human colorectal cancer increased T cell infiltration and tumor destruction in an autologous coculture model »« The 3IC team works on the intestinal immunity in inflammation and cancer, and more specifically on T cells. The intestine presents a particular immune system, constantly stimulated by exogenous antigens from food, commensal microbiota or pathogens. Specific regulations balance the immune response between tolerance of microbiota and food antigens, and protection against pathogens. This immune homeostasis is crucial and its perturbation are involved in several pathologies. Upon epithelial stress and continuous inflammation, an abnormal proinflammatory immune response can induce autoimmune reactions and chronic inflammation diseases, whereas an excessive tolerant phenotype established an immunosuppressive microenvironment favourable to cancer progression. In this tumor context, an antitumor T cell response is clearly engaged but the upregulation of immunosuppressive markers, like the immune checkpoints, allow the tumor immune escape. Immunotherapies targeting these markers, anti-PD-1 and anti-CTLA-4, were developed but presented a weak efficacy in colorectal cancer (CRC).  New therapeutic strategies are necessary. In this project, we studied the antitumor T cell response involved in human CRC. Based on a prospective cohort, our objectives were to better characterize this response to find new potential target for immunotherapy and test their efficacy in our innovative autologous coculture model. We focused on several different pathways including CD39 and CD73. » Contact IRCM : Laurent GROS
En savoir plus

Postdoctoral Position in Modeling of Drug resistant Lung Cancers Microenvironment

The Colinge Laboratory Cancer Bioinformatics and Systems Biology at IRCM (Cancer Research Institute of Montpellier) is looking for a talented postdoctoral fellow. The microenvironment of cancer cells is known to play an important role in tumor progression and resistance. We are looking for a talented post-doctoral scientist to develop models relating the response to different drugs, e.g. platinum-based, with the microenvironment of lung adenocarcinomas (LUADs). This work will integrate on-going developments to infer the cellular interactions taking place in tumor microenvironments (TMEs), both in single cell transcriptomics and bulk analyses (Cabello et al., 2020; Alame et al., 2020). We aim at establishing quantitative and predictive models of treatment outcome based on data acquired from mouse tumors following different dynamics (rapid/slow growth, spontaneous/acquired resistance, response, etc.). The project involves a consortium of expert laboratories in lung cancer and mouse models thereof, bulk and single cell transcriptomics, animal computer tomography, and 3D-imaging. The postdoc position is funded for 2 years.  More 
En savoir plus

Félicitations à Ghita Chabab qui a remporté le prix du public lors de la finale régionale MT180FR "Occitanie-Méditerranée" !!Ghita est financé par le @FRM_officiel et effectue sa thèse à l'IRCM, au sein de l'équipe Immunité et cancer du Dr Nathalie Bonnefoy.
En savoir plus

 Antoine Gleizes a reçu le prix de la meilleure présentation orale lors des journées du CECED, association qui a pour objectif de promouvoir les échanges scientifiques entre chercheurs travaillant dans le domaine des cellules épithéliales digestives. Antoine a été récompensé pour son travail sur l'étude du rôle du co-régulateur RIP140 dans la biologie des cellules souches intestinales normales et cancéreuses au sein de l'équipe Signalisation Hormonale et Cancer de l'IRCM.
En savoir plus

Projet IE 1 an

Publication le 22/03/2021L'équipe "Criblage fonctionnel et ciblage du cancer" recrute un IE débutant pour 1 an sur un projet en collaboration avec l'IRMB et la société MedXCell. La date limite de dépôt des dossiers est le 9 avril à 12h. La description du poste et la procédure de dépôt sont accessibles sur le site
En savoir plus

Responsable scientifique de plateforme

Publication le 19/03/21L’Institut de Recherche en Cancérologie de Montpellier propose un poste d’interface entreactivité de Recherche (40% du temps) et Direction scientifique de la plateforme « ProtéomiqueIdentification et Interactions moléculaires » (PP2I) (60% du temps).PP2I est une plateforme de l’IRCM reliée au Pôle Protéomique de Montpellier (PPM) au seinde BioCampus et intégrée aux réseaux Labex MabImprove et SIRIC Montpellier( Votre mission sera de maintenir et faireprogresser l’expertise de PP2I dans l’étude des interactions moléculaires par des technologieslabel free (SPR, BLI, QCM…) au sein de la région Occitanie.Parallèlement, vous vous impliquerez dans des projets de recherche en lien avec lesthématiques de l’IRCM et/ou PP2I En savoir plus
En savoir plus

The @IRCM_MTP and the @ICM_Montpellier wish to express their profound gratitude to the Mayor, town council and merchants of #Baillargues for their commitment and generous contribution to advancing prostate #Cancer research in the frame of the November event 2020.
En savoir plus

Félicitations au Dr. Julie Constanzo qui vient de recevoir le prix « Jack Fowler » de la Radiation Research Society !

Ce prix récompense un chercheur junior pour son travail remarquable en radio-oncologie, physique médicale et / ou radiobiologie. La recherche du Dr Constanzo porte sur le rôle des vésicules extracellulaires dans l’activation du système immunitaire, dans un contexte de Radiothérapie vectorisée des tumeurs à base d’anticorps monoclonaux radiomarqués. Ce projet est conduit au sein de l’équipe dirigée par le Dr. J-P Pouget « Radiobiologie et Radiothérapie Vectorisée » de l’Institut de Recherche en Cancérologie de Montpellier (IRCM, INSERM U1194). En savoir plus :
En savoir plus

the word of the director

"Together, let's push the boundaries."

«In just 20 years, the Institut de Recherche en Cancérologie de Montpellier (IRCM U1194) has raised its research to the highest international level in the field of fundamental and applied oncology, research carried out in close collaboration with the clinical departments of the Centre de Lutte Contre le Cancer de Montpellier (ICM: Institut du Cancer de Montpellier), and industrial partners. Jointly operated by Inserm, ICM and the University of Montpellier, the IRCM now brings together more than 200 people, researchers, clinicians, technicians and students, organised into 17 research teams supported by efficient technical platforms and support services. In an extremely competitive and rapidly evolving field of research, our greatest challenge is to stay one step ahead, seek excellence, accelerate innovation and transfer to the patient to ultimately help overcome the countless different forms of cancer.Together, let's push the boundaries.»

Claude Sardet, Director of the IRCM

the word of the director


Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol J-L, Calvayrac O, Moll H, Glasson Y, Pirot N, Turtoi A, Cañamero M, Wong K-K, Yarden Y, Casanova E, Soria J-C, Colinge J, Siebel C, Favre G, Paz-Ares L, Maraver A Notch inhibition overcomes resistance to Tyrosine Kinase Inhibitors in EGFR-driven lung adenocarcinoma. J. Clin. Invest.. Oct 31, 2019. doi:10.1172/JCI126896

Combes E, Andrade A, Tosi D, Michaud H-A, Coquel F, Desigaud D, Jarlier M, Coquelle A, Pasero P, Bonnefoy N, Martineau P, Del Rio M, Beijersbergen R, Vezzio-Vie N Inhibition of Ataxia-Telangiectasia Mutated and RAD3-related (ATR) overcomes oxaliplatin resistance and promotes anti-tumor immunity in colorectal cancer. Cancer Res.. Apr 15, 2019. doi:10.1158/0008-5472.CAN-18-2807

Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz L, Roger P, Guiu S, Derocq D, Robin G, Michaud H-A, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget J-P, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7(1):29. doi:10.1186/s40425-019-0498-z

Ladjohounlou R, Lozza C, Pichard A, Constanzo J, Karam J, Le Fur P, Deshayes E, Boudousq V, Paillas S, Busson M, Le Blay M, Jarlier M, Marcatili S, Bardiès M, Bruchertseifer F, Morgenstern A, Torgue J, Navarro-Teulon I, Pouget J-P Drugs that modify cholesterol metabolism alter the p38/JNK-mediated targeted and non-targeted response to alpha and Auger radioimmunotherapy. Clin. Cancer Res.. May 06, 2019. doi:10.1158/1078-0432.CCR-18-3295

Perrot I, Michaud H-A, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Jecko D, Becquart O, Rispaud-Blanc H, Gauthier L, Rossi B, Chanteux S, Gourdin N, Amigues B, Roussel A, Bensussan A, Eliaou J-F, Bastid J, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E, Paturel C, Bonnefoy N Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. Cell Rep. 2019;27(8):2411-2425.e9. doi:10.1016/j.celrep.2019.04.091

Forest E, Logeay R, Géminard C, Kantar D, Frayssinoux F, Heron-Milhavet L, Djiane A The apical scaffold big bang binds to spectrins and regulates the growth of Drosophila melanogaster wing discs. J. Cell Biol.. 2018;217(3):1047-1062. doi:10.1083/jcb.201705107

Arena G, Cissé M, Pyrdziak S, Chatre L, Riscal R, Fuentes M, Arnold J, Kastner M, Gayte L, Bertrand-Gaday C, Nay K, Angebault-Prouteau C, Murray K, Chabi B, Koechlin-Ramonatxo C, Orsetti B, Vincent C, Marine J-C, Etienne-Manneville S, Bernex F, Lombès A, Cameron C, Dubouchaud H, Ricchetti M, Linares L, Le Cam L Mitochondrial MDM2 Regulates Respiratory Complex I Activity Independently of p53. Mol. Cell. 2018;69(4):594-609.e8. doi:10.1016/j.molcel.2018.01.023

Leconet W, Chentouf M, du Manoir S, Chevalier C, Sirvent A, Aït-Arsa I, Busson M, Jarlier M, Radosevic-Robin N, Theillet C, Chalbos D, Pasquet J-M, Pèlegrin A, Larbouret C, Robert B Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis. Clin. Cancer Res.. 2017;23(11):2806-2816. doi:10.1158/1078-0432.CCR-16-1316

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés